Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharm Holdings (NQ: TNXP )

0.2386 -0.0171 (-6.69%)
Streaming Delayed Price Updated: 3:30 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,243,991
Open 0.2501
Bid (Size) 0.2385 (78)
Ask (Size) 0.2386 (1)
Prev. Close 0.2557
Today's Range 0.2220 - 0.2558
52wk Range 0.2347 - 32.32
Shares Outstanding 22,004,159
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine
Tonix Pharmaceuticals and Bilthoven Biologicals have partnered to advance TNX-801, a promising mpox vaccine candidate based on horsepox. Backed by the world's largest vaccine manufacturer, the... 
Via Benzinga
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801
World Health Organization declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) for the second time in two years Worldwide availability and... 
Via FinancialNewsMedia

Performance

YTD
-98.22%
-98.22%
1 Month
-57.78%
-57.78%
3 Month
-95.61%
-95.61%
6 Month
-98.03%
-98.03%
1 Year
-99.21%
-99.21%

More News

Read More
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
Via ACCESSWIRE
What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
Via Benzinga
Peering Into Tonix Pharmaceuticals's Recent Short Interest
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
TNXP Stock Earnings: Tonix Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Tonix Pharmaceuticals' Live Virus Vaccine Candidate Shows Long-Term Protection From Mpox, Smallpox With 1 Dose, Animal Study Suggests
Via Benzinga
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
Via ACCESSWIRE
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Via FinancialNewsMedia
Exposures Product Safety
Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
Via ACCESSWIRE
Tonix Pharmaceuticals receives positive feedback from FDA on Tonmya™ for fibromyalgia management
Via News Direct
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
Via ACCESSWIRE
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Tonix Pharmaceuticals (TNXP) Stock Is Falling
Via Benzinga
7 F-Rated Stocks To Sell in July
Via InvestorPlace
Nano-Cap Tonix Pharmaceuticals Secures Large US Department of Defense Contract
Via Benzinga
AMZN Stock Alert: Amazon Just Joined the $2 Trillion Club
Via InvestorPlace
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Nike, Micron And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
7 F-Rated Penny Stocks to Avoid This June
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.